I suppose mostly because a different drug in the pipeline on May 15 was delayed, "Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism to Aug. 14 2024"
